<DOC>
	<DOCNO>NCT01245556</DOCNO>
	<brief_summary>The purpose study identify safe tolerable dose BMS-908662 combination ipilimumab ; evaluate anti-tumor response BMS-908662 administer combination ipilimumab .</brief_summary>
	<brief_title>Safety Efficacy Study BMS-908662 Combination With Ipilimumab Subjects With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion : Male female subject ≥ 18 year age histologic cytologic diagnosis Stage III Stage IV ( unresectable ) melanoma Enrollment cohort expansion limit subject whose tumor demonstrate BRaf V600E mutation ECOG ≤ 1 Adequate organ &amp; marrow function Exclusion : Uncontrolled significant cardiovascular disease Cohort expansion : Prior therapy RAF inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>